中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2009年
7期
1153-1154
,共2页
唐皓%梁艳冰%翟诚顺%马中富
唐皓%樑豔冰%翟誠順%馬中富
당호%량염빙%적성순%마중부
冠状动脉疾病%阿托伐他汀%炎性因子
冠狀動脈疾病%阿託伐他汀%炎性因子
관상동맥질병%아탁벌타정%염성인자
Coronary disease%Atorvastatin%Inflamatory factor
目的 探讨急性冠脉综合征(ACS)患者外周血单个核细胞环氧化酶2(COX-2)、血小板活化因子乙酰水解酶(PAF-AH)与血清超敏C反应蛋白(hsCRP)水平的变化及阿托伐他汀对它们的影响与意义.方法 测定健康对照组(40例)、ACS组(45例)治疗前后外周血单个核细胞的COX-2、PAF-AH及hsCRP水平,并作比较.结果 健康对照组COX-2[(33.8±4.6)ng/ml]、PAF-AH[(30.2±1.5)μmol·min-1·L-1]、hsCRP[(1.1±0.8)g/L],与ACS组治疗前COX-2[(50.4±5.8)ng/ml]、PAF-AH[(18.7±3.1)μmol·min-1·L-1]、hsCRP[(19.3+5.6)g/L]差异有统计学意义(P<0.05),ACS组治疗后COX-2[(38.1±3.2)ng/ml]、PAF-AH[(28.0±2.1)μmol·win-1·L-1]、hsCRP[(7.4±1.8)g/L]与治疗前差异有统计学意义(P<0.05).结论 炎性因子COX-2、PAF-AH、hsCRP与ACS的发病明显相关,阿托伐他汀可降低ACS患者的COX-2、hsCRP,升高PAF-AH,对减轻炎症反应、稳定斑块起着重要作用.
目的 探討急性冠脈綜閤徵(ACS)患者外週血單箇覈細胞環氧化酶2(COX-2)、血小闆活化因子乙酰水解酶(PAF-AH)與血清超敏C反應蛋白(hsCRP)水平的變化及阿託伐他汀對它們的影響與意義.方法 測定健康對照組(40例)、ACS組(45例)治療前後外週血單箇覈細胞的COX-2、PAF-AH及hsCRP水平,併作比較.結果 健康對照組COX-2[(33.8±4.6)ng/ml]、PAF-AH[(30.2±1.5)μmol·min-1·L-1]、hsCRP[(1.1±0.8)g/L],與ACS組治療前COX-2[(50.4±5.8)ng/ml]、PAF-AH[(18.7±3.1)μmol·min-1·L-1]、hsCRP[(19.3+5.6)g/L]差異有統計學意義(P<0.05),ACS組治療後COX-2[(38.1±3.2)ng/ml]、PAF-AH[(28.0±2.1)μmol·win-1·L-1]、hsCRP[(7.4±1.8)g/L]與治療前差異有統計學意義(P<0.05).結論 炎性因子COX-2、PAF-AH、hsCRP與ACS的髮病明顯相關,阿託伐他汀可降低ACS患者的COX-2、hsCRP,升高PAF-AH,對減輕炎癥反應、穩定斑塊起著重要作用.
목적 탐토급성관맥종합정(ACS)환자외주혈단개핵세포배양화매2(COX-2)、혈소판활화인자을선수해매(PAF-AH)여혈청초민C반응단백(hsCRP)수평적변화급아탁벌타정대타문적영향여의의.방법 측정건강대조조(40례)、ACS조(45례)치료전후외주혈단개핵세포적COX-2、PAF-AH급hsCRP수평,병작비교.결과 건강대조조COX-2[(33.8±4.6)ng/ml]、PAF-AH[(30.2±1.5)μmol·min-1·L-1]、hsCRP[(1.1±0.8)g/L],여ACS조치료전COX-2[(50.4±5.8)ng/ml]、PAF-AH[(18.7±3.1)μmol·min-1·L-1]、hsCRP[(19.3+5.6)g/L]차이유통계학의의(P<0.05),ACS조치료후COX-2[(38.1±3.2)ng/ml]、PAF-AH[(28.0±2.1)μmol·win-1·L-1]、hsCRP[(7.4±1.8)g/L]여치료전차이유통계학의의(P<0.05).결론 염성인자COX-2、PAF-AH、hsCRP여ACS적발병명현상관,아탁벌타정가강저ACS환자적COX-2、hsCRP,승고PAF-AH,대감경염증반응、은정반괴기착중요작용.
Objective To study the level of cyclooxygenase-2 (COX-2) and platelet-activating factor acetyl-hydrolase(PAF-AH) and high sensitive C reactive protein(hsCRP) on peripheral blood mononuclear cells in Acute Coronary Syndrome(ACS) patients and the effect of atorvastatin on them and the clinical significance. Methods To measure and compare the content of COX-2,PAF-AH and hsCRP in normal control group and ACS group(before and after treatment). Result The content of COX-2,PAF-AH and hsCRP are significantly different between normal con-trol group and ACS group (before treatment) (P < 0.05), and between ACS group (before treatment) and ACS group (after treatment) too(P < 0.05). Conclusions The inflammatory cytokines COX-2,PAF-AH and haCRP have sig-nificant correlation with the occurance of ACS. Atorvastatin can decrease COX-2 and hsCRP level, and can increase PAF-AH level. So atorvastatin takes an important role in lessening inflamatory reaction level in ACS patients.
